Claim 1: add PD-L1 human (SEQ ID No.1) antibody；It is characterized by a light chain (LC) and a heavy chain (HC),The light chain includes a variable light chain region (LCVR), and the heavy chain includes a variable heavy chain region (hcvr),Among them, LCVR includes the decision regions of LCDR1, LCDR2 and LCDR3 light chain complementarity, which are composed of the sequence of amino acid sgsnigstvn (SEQ ID No.5),YGNSNRPS (SEQ ID N 6)And qsydsslszv (SEQ ID No.7),Hcvr includes HCDR1, HCDR2, HCDR3 and other heavy chain complementary determining regions, including the amino acid kasggtfssyais sequence (SEQ ID No.2),GIIPIFGTANYAQKFQG (SEQ ID N 3)y ARSPDYSPYYYYGMDV (SEQ ID N 4)Namely Claim 7: a mammalian cell, which is characterized in that it contains a DNA molecule and consists of a polynucleotide sequence, which encodes a polypeptide sequence, including an amino acid sequence of SEQ ID 11 and a polynucleotide sequence, which encodes a polypeptide sequence, including an amino acid sequence of SEQ ID. No. 10, in which the cell can express antibody, including a light chain, which contains the amino acid sequence of CAS No. 11 and a heavy chain, which contains the amino acid sequence of CAS No. 10. Requirement 8: the process of producing antibodies,It is characterized by a light chain containing the amino acid sequence of SEQ ID 11 and a heavy chain containing the amino acid sequence of SEQ ID 10, including culturing mammalian cells under conditions according to item 7, so as to make the antibody positive and recover Antibody expression. Claim 10: a pharmaceutical ingredient characterized by the inclusion of antibodies in accordance with any one of the requirements of 1-6 or 9, as well as an acceptable carrier, diluent, or former pharmacist. Requirement 12: method of compliance 11Cancer is characterized by melanoma, lung cancer, head and neck cancer, rectal cancer, pancreatic cancer, gastric cancer, kidney cancer, bladder cancer, prostate cancer, breast cancer, ovarian c
